Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000733251 | SCV000861296 | pathogenic | not provided | 2018-05-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000733251 | SCV001409968 | pathogenic | not provided | 2023-07-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.His112Serfs*6) in the TRMU gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TRMU are known to be pathogenic (PMID: 19732863, 23625533). This variant is present in population databases (rs756600903, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with TRMU-related conditions. ClinVar contains an entry for this variant (Variation ID: 597202). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002499369 | SCV002809710 | likely pathogenic | Aminoglycoside-induced deafness; Acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins | 2022-04-18 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003472267 | SCV004204353 | likely pathogenic | Aminoglycoside-induced deafness | 2023-10-03 | criteria provided, single submitter | clinical testing |